title: CC-122 immunomodulatory effects in refractory patients with diffuse large B-cell lymphoma.
abstract: In the three patients included in a phase I clinical trial (NCT01421524), we report the immunomodulatory effects and efficacy of CC-122, a novel pleiotropic pathway modifier compound originally developed for broad diffuse large B-cell lymphoma (DLBCL). The chemical structure of CC-122 includes the glutarimide moiety that is known to modulate the immune response. The immunomodulatory agents including lenalidomide represent a promising therapeutic strategy targeting tumors in B-cell lymphoid malignancies. We observed that CC-122 might regulate the NK phenotype and its activity due to the reduced accumulation of myeloid-derived suppressor cell and eventually decrease the Tregs subsets. Finally, the activation of T cells through co-stimulatory molecule (CD28) was detected as a delayed CC-122 effect. In this context, CC-122 arises as an alternative option for DLBCL patients refractory to the traditional chemotherapeutic agents.
authors.affiliation: The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain; Tumor Immunology Laboratory, IdiPAZ, Madrid, Spain; Center for Biomedical Research Network, CIBEres, Madrid, Spain.
authors.forename: Carolina
authors.initials: C
authors.lastname: Cubillos-Zapata
authors.affiliation: Lymphoma Unit, Oncohealth Institute, Foundation Jimenez Diaz University Hospital, Health Research Institute IIS-FJS, Autonomous University of Madrid, Madrid, Spain; START Madrid FJD, Phase 1 Clinical Trials Unit, Foundation Jiménez Díaz University Hospital, Madrid, Spain.
authors.forename: Raúl
authors.initials: R
authors.lastname: Cordoba
authors.affiliation: The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain; Tumor Immunology Laboratory, IdiPAZ, Madrid, Spain.
authors.forename: José
authors.initials: J
authors.lastname: Avendaño-Ortiz
authors.affiliation: The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain; Tumor Immunology Laboratory, IdiPAZ, Madrid, Spain.
authors.forename: Cristina
authors.initials: C
authors.lastname: Arribas-Jiménez
authors.affiliation: The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain; Tumor Immunology Laboratory, IdiPAZ, Madrid, Spain; Center for Biomedical Research Network, CIBEres, Madrid, Spain.
authors.forename: Enrique
authors.initials: E
authors.lastname: Hernández-Jiménez
authors.affiliation: The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain; Tumor Immunology Laboratory, IdiPAZ, Madrid, Spain; Center for Biomedical Research Network, CIBEres, Madrid, Spain.
authors.forename: Víctor
authors.initials: V
authors.lastname: Toledano
authors.affiliation: Lymphoma Unit, Oncohealth Institute, Foundation Jimenez Diaz University Hospital, Health Research Institute IIS-FJS, Autonomous University of Madrid, Madrid, Spain; START Madrid FJD, Phase 1 Clinical Trials Unit, Foundation Jiménez Díaz University Hospital, Madrid, Spain.
authors.forename: Teresa
authors.initials: T
authors.lastname: Villaescusa
authors.affiliation: Lymphoma Unit, Oncohealth Institute, Foundation Jimenez Diaz University Hospital, Health Research Institute IIS-FJS, Autonomous University of Madrid, Madrid, Spain; START Madrid FJD, Phase 1 Clinical Trials Unit, Foundation Jiménez Díaz University Hospital, Madrid, Spain.
authors.forename: Víctor
authors.initials: V
authors.lastname: Moreno
authors.affiliation: The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain; Tumor Immunology Laboratory, IdiPAZ, Madrid, Spain; Center for Biomedical Research Network, CIBEres, Madrid, Spain.
authors.forename: Eduardo
authors.initials: E
authors.lastname: López-Collazo
keywords: CC-122 treatment; DLBCL patients; immune response